What’s new in HPV-associated cancers in men?

Like cervical cancer, the vast majority (90%) of anal cancers and some oral cancers are caused by human papillomavirus (HPV). In some populations, specifically men who have sex with men (MSM) living with HIV, the rates of anal cancer are over 50-times the rate in the general population, and despite decades’ worth of effective HIV therapy, anal cancer rates continue to climb in MSM living with HIV. Anal cancer is one of the most common cancers in individuals living with HIV, and is a leading cause of death in these individuals. There are a number of ongoing large studies in Canada, the USA, and Australia examining the prevention, natural history and screening/treatment of HPV-associated anal pre-cancers, and emerging interest in HPV-associated oral cancers. This talk will review recent evidence from these trials, and discuss directions forward for HPV-associated cancers in males. Bio: Dr. Troy Grennan is currently the Physician Lead for the Provincial HIV/STI Program at the BC Centre for Disease Control, as well as a Clinical Assistant Professor in the Division of Infectious Diseases at the University of British Columbia. Following training in internal medicine, infectious diseases, and medical microbiology, he completed a CIHR Canadian HIV Trials Network postdoctoral fellowship examining human papillomavirus (HPV) in HIV-positive men who have sex with men (MSM). His research and clinical work currently focuses on HIV and STI prevention, as well as HPV and anal cancer screening, with a particular focus on MSM. He is currently co-PI on the CIHR Team Grant “HPV Screening and Vaccine Evaluation in HIV-Positive MSM”, and also co-leads two grants on novel syphilis prevention using doxycycline chemoprophylaxis.

BC CDC Presenters

2/25/2020 8:00:00 PM